• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

作者信息

MacNair Kyle, Bugden Shawn

出版信息

Can J Cardiol. 2007 May 1;23(6):481-2; author reply 483. doi: 10.1016/s0828-282x(07)70793-6.

DOI:10.1016/s0828-282x(07)70793-6
PMID:17549843
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2650670/
Abstract
摘要

相似文献

1
Re: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.关于：加拿大心血管学会立场声明——血脂异常的诊断与治疗及心血管疾病预防的建议
Can J Cardiol. 2007 May 1;23(6):481-2; author reply 483. doi: 10.1016/s0828-282x(07)70793-6.
2
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.2009年加拿大心血管学会/加拿大成人血脂异常诊断与治疗及心血管疾病预防指南——2009年推荐意见
Can J Cardiol. 2009 Oct;25(10):567-79. doi: 10.1016/s0828-282x(09)70715-9.
3
[Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011].[捷克动脉粥样硬化协会委员会（CSAT）对2011年发布的欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常诊断和治疗指南的意见]
Vnitr Lek. 2013 Feb;59(2):120-6.
4
[Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].[西班牙心血管疾病预防跨学科委员会及西班牙心脏病学会关于血脂异常管理的立场声明。欧洲和美国指南的差异]
Semergen. 2015 Apr;41(3):149-57. doi: 10.1016/j.semerg.2014.05.020. Epub 2014 Nov 14.
5
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.2012 年加拿大心血管学会血脂异常诊断和治疗指南更新：预防成年人心血管疾病。
Can J Cardiol. 2013 Feb;29(2):151-67. doi: 10.1016/j.cjca.2012.11.032.
6
[Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.].欧洲心脏病学会和欧洲动脉粥样硬化学会关于心血管疾病预防和血脂异常管理。动脉粥样硬化诊断和血脂异常治疗（2016年）：基础S.G.
Kardiologiia. 2017 Mar;57(3):85-89.
7
[Essence of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and Treatment Guide for Dyslipidemia 2013--Current Strategy for the Lipid Assessment].[日本动脉粥样硬化协会（JAS）日本动脉粥样硬化性心血管疾病诊断与预防指南2012版及血脂异常治疗指南2013——血脂评估的当前策略]
Rinsho Byori. 2014 Sep;62(9):878-83.
8
Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines.西班牙心血管疾病预防跨学科委员会及西班牙心脏病学会关于血脂异常管理的立场声明。欧洲和美国指南之间的差异。
Rev Esp Cardiol (Engl Ed). 2014 Nov;67(11):913-9. doi: 10.1016/j.rec.2014.05.008. Epub 2014 Aug 3.
9
Increased Lp(a) Workload Volumes Reflect Uptake of the 2021 Canadian Cardiovascular Society Guidelines for Management of Dyslipidemia.
Can J Cardiol. 2024 Sep;40(9):1603-1605. doi: 10.1016/j.cjca.2024.02.019. Epub 2024 Mar 1.
10
Recommendation for the management of dyslipidemia in Poland - Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy.波兰血脂异常管理建议——索波特第三次声明。由波兰心脏学会心血管药物治疗工作组认可的跨学科专家立场声明。
Cardiol J. 2018;25(6):655-665. doi: 10.5603/CJ.2018.0141.

本文引用的文献

1
Review: cholesterol-lowering treatment with statins reduces all-cause mortality in persons at risk.
ACP J Club. 2006 May-Jun;144(3):62.
2
Statins in primary prevention: uncertainty in women, elderly.他汀类药物用于一级预防：女性和老年人中的不确定性
Am Fam Physician. 2006 Mar 15;73(6):973-4; author reply 974.
3
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.大剂量他汀类药物治疗对冠状动脉粥样硬化消退的影响：ASTEROID试验
JAMA. 2006 Apr 5;295(13):1556-65. doi: 10.1001/jama.295.13.jpc60002. Epub 2006 Mar 13.
4
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.高剂量阿托伐他汀与常规剂量辛伐他汀用于心肌梗死后二级预防：IDEAL研究：一项随机对照试验。
JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437.
5
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.降低胆固醇治疗的疗效与安全性：对他汀类药物14项随机试验中90,056名参与者数据的前瞻性荟萃分析
Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.
6
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.阿托伐他汀强化降脂治疗稳定型冠心病患者
N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8.
7
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.阿托伐他汀在2型糖尿病中对心血管疾病的一级预防：合作阿托伐他汀糖尿病研究（CARDS）：多中心随机安慰剂对照试验
Lancet. 2004;364(9435):685-96. doi: 10.1016/S0140-6736(04)16895-5.
8
Dyslipidemia guidelines.血脂异常指南。
CMAJ. 2004 Jul 20;171(2):118; author reply 118-9. doi: 10.1503/cmaj.1031820.
9
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.急性冠状动脉综合征后使用他汀类药物强化降脂与中度降脂的比较。
N Engl J Med. 2004 Apr 8;350(15):1495-504. doi: 10.1056/NEJMoa040583. Epub 2004 Mar 8.
10
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.强化降脂治疗与中度降脂治疗对冠状动脉粥样硬化进展的影响：一项随机对照试验。
JAMA. 2004 Mar 3;291(9):1071-80. doi: 10.1001/jama.291.9.1071.